Skip to main content
PULSE BIOSCIENCES, INC. logo

PULSE BIOSCIENCES, INC. — Investor Relations & Filings

Ticker · PLSE ISIN · US74587B1017 LEI · 529900NJUBI06118FM73 US Professional, scientific and technical activities
Open in API
Filings indexed 600 across all filing types
Latest filing 2026-06-10 Regulatory Filings
Country US United States of America
Listing US PLSE

About PULSE BIOSCIENCES, INC.

https://www.pulsebiosciences.com/

Pulse Biosciences, Inc. is a bioelectric medicine company developing its proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology. This non-thermal energy platform delivers nanosecond-duration electrical pulses to ablate cellular tissue while sparing adjacent noncellular structures. The company's primary focus is on advancing treatments in cardiology, particularly for atrial fibrillation, through investigational devices such as the CellFX® nsPFA™ 360 Cardiac Catheter and a surgical cardiac clamp. Pulse Biosciences is also developing its technology for non-cardiac applications, including the use of percutaneous electrodes for treating conditions like benign thyroid nodules. The nsPFA technology aims to provide a potentially safer and more efficient alternative to conventional thermal ablation methods across a broad spectrum of medical procedures.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K “Current Report” filed with the U.S. SEC under the Exchange Act describing other events—specifically, an irrevocable election to redeem outstanding warrants—and attaches a press release. It contains no standalone financial statements or management discussion, nor is it an earnings release, board change, or proxy. This is a regulatory announcement/report to the SEC, fitting the fallback category “Regulatory Filings (RNS).”
2026-06-10 English
FORM 10-Q
Interim / Quarterly Report Q1 2026
2026-05-14 English
DEF 14A - PULSE BIOSCIENCES, INC. (0001625101) (Filer)
Proxy Solicitation & Information Statement
2026-05-11 English
8-K - PULSE BIOSCIENCES, INC. (0001625101) (Filer)
Capital/Financing Update Classification · 89% confidence The document is an SEC Form 8-K current report under Item 8.01 “Other Events,” announcing that the Board approved an Equity Distribution Agreement (an at-the-market offering) to sell up to $59.98 million of common stock through a sales agent and noting expected affiliate purchases. This is a financing/capital‐raising update, not the full financial statements or Q&A transcript. It falls under Capital/Financing Update (CAP).
2026-05-06 English
8-K - PULSE BIOSCIENCES, INC. (0001625101) (Filer)
Earnings Release Classification · 85% confidence The document is a Form 8-K Current Report with Item 2.02 “Results of Operations and Financial Condition,” furnishing a press release with quarterly financial results for Q1 2026 (preliminary key highlights only). This is typical for an earnings release announced via an 8-K rather than a full interim/quarterly financial report (10-Q or IR). Therefore, it fits the “Earnings Release” category. Q1 2026
2026-05-04 English
8-K - PULSE BIOSCIENCES, INC. (0001625101) (Filer)
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated April 25, 2026. It announces additional key findings from a clinical study and includes a press release and an updated investor presentation as exhibits. The text explicitly states that the investor presentation is summary information and is used for presentations to investors and analysts. The document does not contain detailed financial statements or comprehensive financial analysis but rather disclosures and updates about clinical study results and investor materials. This fits the definition of an Investor Presentation (IP) rather than a full financial report or earnings release. The length of the document (6192 characters) and the content confirm it is a report containing an investor presentation and press release, not just an announcement of a report publication. Therefore, the appropriate classification is Investor Presentation (IP).
2026-04-27 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.